Financials data is unavailable for this security.
View more
Year on year Novo Nordisk A/S grew net income 13.33% from 42.14bn to 47.76bn primarily through revenue growth (126.95bn to 140.80bn). For while the costs associated with cost of goods, selling, general and administrative and debt all increased as a percentage of sales, the 10.91% growth in revenues contributed enough to still see net income improve.
Gross margin | 83.38% |
---|---|
Net profit margin | 33.11% |
Operating margin | 42.15% |
Return on assets | 29.15% |
---|---|
Return on equity | 78.92% |
Return on investment | 57.87% |
More ▼
Cash flow in DKKView more
In 2021, cash reserves at Novo Nordisk A/S fell by 1.51bn. However, the company earned 55.00bn from its operations for a Cash Flow Margin of 39.06%. In addition the company used 31.61bn on investing activities and also paid 25.49bn in financing cash flows.
Cash flow per share | 23.86 |
---|---|
Price/Cash flow per share | 23.43 |
Book value per share | 29.24 |
---|---|
Tangible book value per share | 10.20 |
More ▼
Balance sheet in DKKView more
Current ratio | 0.9052 |
---|---|
Quick ratio | 0.693 |
Total debt/total equity | 0.3829 |
---|---|
Total debt/total capital | 0.2769 |
More ▼
Growth rates in DKK
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 14.29% and 15.15%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Biotechnology & Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked the highest relative to its industry peers.
Div yield(5 year avg) | 2.16% |
---|---|
Div growth rate (5 year) | 6.47% |
Payout ratio (TTM) | 36.62% |
EPS growth(5 years) | 6.74 |
---|---|
EPS (TTM) vs TTM 1 year ago | 16.48 |
More ▼